Genetic engineering to enhance microbial interference and related therapeutic applications: Can biotechnology augment competitive exclusion for novel therapeutic approaches?

Nature Biotechnology

Volumn 14, Issue 4, 1996, Pages 444-447

  Chang, Henry ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL COLONIZATION; BACTERIUM; BIOTECHNOLOGY; GENETIC ENGINEERING; HUMAN; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; REVIEW; SKIN DISEASE; TOOTH PLAQUE;

BACTERIA (MICROORGANISMS);

EID: 0029950587     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt0496-444     Document Type: Article

References (65)

1. This literature review was performed while at the Naval Medical Research Institute, Bethesda, MD, and does not represent the official views of the U.S. Government.
2. Bibel D.J. Bacterial interference, bacteriotherapy, and bacterioprophylaxis. In: Aly R., Shinefield H.R., (eds.). Bacterial Interference. CRC Press, Boca Raton, Florida, 1982:1-12.
3. Fleming A. History and development of penicillin. In: Penicillin: Its Practical Application. Fleming A., editor. Philadelphia: Blakiston, 1946:1-33.
4. Jakab G.J. Mechanisms of bacterial superinfections in viral pneumonias. Schweiz Med Wochenschr 1985;115:75-86.
5. Gremillion D.H., Crawford G.E. Measles pneumonia In young adults. An analysis of 106 cases. Am J Med 1981;71:539-42.
6. Joklik W.F., Willett H.P., Amos D.B., Wilfert C.M., (eds.). Zinsser Microbiology, 20th ed., Norwalk, CT: Appleton & Lange, 1992: 395-8.
7. Shinefield H.R., Ribble J.C., Boris M., Eichenwald H.F. Bacterial interference: its effect on nursery acquired infection with Staphylococcus aureus. Am J Dis Child 1963:105:646-54 and 683-8.
8. Houck P.W., Nelson J.D., Kay J.L. Fatal septicemia due to Staphylococcus aureus 502A. Am J Dis Child 1972;123:45-8.
9. Sprunt K., Leidy G. The use of bacterial interference to prevent infection. Can J Microbiol 1988;34:332-8.
10. Calculated from: Protein data (Bacterial cells: E.coli or Salmonella typhimurium). In Reference appendix. New England Biolabs 1993/94 catalog. Beverly, MA: New England Biolabs, 1993: 207.
11. Sahl H.G. Bactericidal cationic peptides involved in bacterial antagonism and host defence. Microbiol Sci 1985;2:212-7.
12. Scully B.E., Briones F., Gu J.W., Neu H.C. Mupirocin treatment of nasal staphlococcal colonization. Arch Int Med 1992;152:353-6.
13. Kolenbrander P.E., Ganeshkumar N., Cassels F.J., Hughes C.V. Coaggregation: specific adherence among human oral plaque bacteria. FASEB J 1993;7:406-13.
14. Johnson K.P., Hillman J.D. Competitive properties of lactate dehydrogenase mutants of the oral bacterium Streptococcus mutans in the rat. Arch Oral Biol 1982;27:513-6.
15. Tanzer J.M., Kurasz A.B., Clive J. Competitive displacement of mutans streptococci and inhibition of tooth decay by Streptococcus salivarius TOVE-R. Infect Immun 1985;48:44-50.
16. Hillman J.D., Dzuback A.L., Andrews S.W. Colonization of the human oral cavity by a Streptococcus mutans mutant producing increased bacteriocin. J Dent Res 1987;66:1092-4.
17. Lehner T, Ma J.K., Kelly C.G. A mechanism of passive immunization with monoclonal antibodies to a 185, 000 M(r) streptococcal antigen. Adv Exp Med Biol 1992;327:151-63.
18. Macrina F.L., Dertzbaugh M.T., Halula M.C., Krah E.R. 3rd, Jones K.R. Genetic approaches to the study of oral microflora: a review. Crit Rev Oral Biol Med 1990;1:207-27.
19. Marshall J.C. The ecology and immunology of the gastrointestinal tract in health and critical illness. J Hosp Infect 1991;19(Suppl. C):7-17.
20. Lidbeck A., Nord C.E. Lactobacilli and the normal human anaerobic microflora. Clin Infect Dis 1993;16(Suppl.4):S181-7.
21. Metchnikoff E. Recherches sur le cholera et le vibrions. Ann Inst Pasteur (Paris) 1894;8:529-89.
22. Rettger L.F., Levy M.N., Weinstein L., Weiss J.E. Lactobacillus acidophilus and its therapeutic application. New Haven, CT: Yale University Press, 1935.
23. Reid G., Bruce A.W., McGroarty J.A., Cheng K.J., Costerton J.W. Is there a role for lactobacilli in prevention of urogenital and intestinal infections? Clin Microbiol Rev 1990;3:335-44.
24. Smith H. Virulence determinants of Escherichia coli: Present knowledge and questions. Can J Microbiol 1992;38:747-52.
25. Wells C.L., Maddaus M.A., Jechorek R.P., Simmons R.L. Role of intestinal anaerobic bacteria in colonization resistance. Eur J Clin Microbiol Infect Dis 1988;7:107-13.
26. Tazume S., Hashimoto K., Sasaki S. Intestinal flora and bile acid metabolism. Nippon Saikingaku Zassi 1979;34:745-54.
27. Goncharova G.I., Semenova L.P., Liannaia A.M., Kozlova E.R, Donskikh E.E. Human bifidobacterium flora, its normalizing and protective functions. Antibiot Med Biotekhnol 1987;32:179-83.
28. Hentges D.J. Inhibition of Shigella by the normal intestinal flora. In: ref. 2.
29. Hummel R.P., Ostreicher E.J., Maley M.P., MacMillan B.G. Inhibition of Candida albicans by Escherichia coli in vitro and in the germfree mouse. J Surg Res 1973;15:53-8.
30. Gutorova L.D., Karimova D.Kh., Molochaeva I.S., Riazanova A.I., Mukhamadieva M.Kh. Effect of enteroviruses on the ecology of intestinal bacteria. Vopr Virusol 1981; 2:234-6.
31. Lasch E.E., Abed Y., Gerichter C.B., Massri M.E., Marcus O., Hensher R., Goldblum N. Results of a program combining live and killed polio vaccines. Isr J Med Sci 1983;19:1021-3.
32. Kelly S., Sanderson W.W., Neidl C. Removal of enteroviruses from sewage by activated sludge. J Water Pollut Contr Fed 1961;33:1056-62.
33. Yates M.V., Stetzenbach L.D., Gerba C.R, Sinclair N.A. The effect of indigenous bacteria on virus survival in ground water. J Environ Sci Health 1990;A25:81-100.
34. Voroshilova M.K. Potential use of nonpathogenic enteroviruses for control of human disease. Prog Med Virol 1989;36:191-202.
35. Whitaker-Dowling P., Youngner J.S. Viral interference-dominance of mutant viruses over wildtype virus in mixed infections. Microbiol Rev 1987;51:179-191.
36. Acheson D.W.K. Enterotoxins in acute infective diarrhoea. J Infect, 1992;24:225-45.
37. Lerner R.A., Kang A.S., Bain J.D., Burton D.R., Barbas, C.F., 3rd. Antibodies without immunization. Science 1992; 258:1313-4.
38. Bokkenheuser V. The friendly anaerobes. Clin Infect Dis 1993;16(Suppl.4):S427-34.
39. Alving C.R., Swartz G.M. Jr. Antibodies to cholesterol, cholesterol conjugates, and liposomes: implications for atherosclerosis and autoimmunity. Crit Rev Immunol 1991;10:441-53.
40. Newman D. The treatment of cystitis by intravesical injections of lactic bacillus cultures. Lancet 1915;2:330-32.
41. Bruce A.W., Reid G. Intravaginal instillation of lactobacilli for prevention of recurrent urinary tract infections. Can J Microbiol 1988;34:339-43.
42. Spiegel CA. Bacterial vaginosis. Clin Microbiol Rev 1991;4:485-502.
43. Friedlander A., Druker M.M., Schachter A. Lactobacillus acidophilus and vitamin B complex in the treatment of vaginal Infection. Panminerva Med 1986;28:51-3.
44. Skarin A., Sylwan J. Vaginal lactobacilli inhibiting growth of Gardnerella vaginalis, Mobiluncus, and other bacterial species cultured from vaginal content of women with bacterial vaginosis. Acta Pathol Microbiol Scand Sect B 1986;94: 399–403.
45. Andersch B., Lindell D., Dahlen I., Brandberg A. Bacterial vaginosis and the effect of intermittent prophylactic treatment with an acid lactate gel. Gynecol Obstet Invest 1990; 30:114-9, erratum in 1991;31:7.
46. Polonelli L., Archbusacci C., Sestito M., Morace G. Killer system: a simple method for differentiating Candida albicans strains. J Clin Microbiol 1983;17:774-80.
47. Wickner R.B. Double-stranded and single-stranded RNA viruses of Saccharomyces cerevisiae. Annu Rev Microbiol 1992;46:34775.
48. Tipper D.J., Schmitt M.J. Yeast dsRNA viruses: replication and killer phenotypes. Mol Microbiol 1991;5:2331-8.
49. Kreiss J., Ngugi E., Holmes K., Ndinya-Achola J., Waiyaki P., Roberts P.L, Ruminjo I., Sajabi R., Kimata J., Fleming T.R. Efficacy of nonoxynol 9 contraceptive sponge use in preventing heterosexual acquisition of HIV In Nairobi prostitutes. JAMA 1992;268:477-82.
50. Truneh A., Frescatore R.L., Thiem P., Leary J.J., Rosenberg M., Hanna N., Sweet R., Bugelski P.J. Humoral response of cynomolgus macaques to human soluble CD4: antibody reactivity restricted to xeno-human determinants. Cell Immunol 1990; 131:98-108.
51. Reimann K.A., Burkly L.C., Burrus B., Waite B.C., Lord C.I., Letvin N.L. In vivo administration to rhesus monkeys of a CD4-specific monoclonal antibody capable of blocking AIDS virus replication. AIDS Res Hum Retroviruses 1993; 9:199-207.
52. Mohan P. Anti-AIDS drug development: challenges and strategies. Pharm Res 1992;9:703-14.
53. Levy J.A. Pathogenesis of human immunodeficiency virus infection. Microbiol Rev 1993;57:183-289.
54. Pestka S., Langer J.A., Zoon K.C., Samuel C.E. Interferons and their actions. Annu Rev Biochem 1987;56:727-77.
55. Leer R.J., van-Luijk N., Posno M., Pouwels P.H. Structural and functional analysis of two cryptic Plasmids from Lactobacillus pentosus MD353 and Lactobacillus plan. Mol Gen Genet 1992; 234:265-74.
56. McGroarty J.A., Tomeczek L., Pond D.G., Reid G., Bruce A.W. Hydrogen peroxide production by Lactobacillus species: Correlation with susceptibility to the spermicidal compound nonoxynol-9. J Infect Dis 1992;165:1142-4.
57. Lo S.C, Hayes M.M., Wang R.Y., Pierce P.F., Kotani H., Shih J.W. Newly discovered mycoplasma isolated from patients infected with HIV. Lancet 1991;338:1415-8.
58. Lenski R.E. Evaluating the fate of genetically modified organisms in the environment: Are they inherently less fit? Experientia 1993:49:201-9.
59. Pickup R.W., Morgan J.A.W., Winstanley C., Saunders J.R. Implications for the release of genetically engineered organisms. J Appl Bact Symp (Suppl) 1991;70:19S-30S.
60. Wickman K. Burn model. In: ref. 2.
61. Bell G.I., Fong N.M., Stempien M.M., Wormsted M.A., Caput D., Ku L, Urdea M.S., Rail L.B., Sanchez-Pescador R. Human epidermal growth factor precursor: cDNA sequence, expression in vitro and gene organization. Nucleic Acids Res 1986;14:8427-46.
62. Finch P.W., Rubin J.S., Miki T, Ron D., Aaronson S.A. Human KGF is FGF-related with properties of a paracrine effector of epithelial cell growth. Science 1989;245:752-5.
63. Kurokawa T., Sasada R., Iwane M., Igarashi K. Cloning and expression of cDNA encoding human basic fibroblast growth factor. FEBS Lett 1987;213:189-94.
64. Rail L.B., Scott J., Bell G.I. Human insulin-like growth factor I and II messenger RNA: Isolation of complementary DNA and analysis of expression. Meth Enzymol 1987;146:239-48.
65. Urushizaki Y., Niitsu Y, Terui T., Koshida Y, Mahara K., Kohgo Y., Urushizaki I., Takahashi Y, Ito H. Cloning and expression of the gene for human transforming growth factor-beta in Escherichia coli. Tumor Res 1987;22:41-55.